-
Je něco špatně v tomto záznamu ?
Estimation of once-daily amikacin dose in critically ill adults
M. Šíma, J. Hartinger, T. Cikánková, O. Slanař,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, pozorovací studie
- MeSH
- amikacin aplikace a dávkování farmakokinetika MeSH
- antibakteriální látky aplikace a dávkování farmakokinetika MeSH
- gramnegativní bakteriální infekce farmakoterapie MeSH
- kritický stav * MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
This study aimed at investigating variables affecting amikacin pharmacokinetics in order to propose optimal initial dosing in critically ill adult patients treated with once-daily amikacin regimen. Amikacin pharmacokinetics was calculated based on plasma concentrations using one compartmental analysis. Relationships between pharmacokinetic parameters and demographic/clinical data were explored in linear regression models. Simulated dose and dosing intervals were derived from body size descriptors and estimated creatinine clearances for each patient. Amikacin volume of distribution best correlated with body surface area, while amikacin clearance was best predicted by CKD-EPI creatinine clearance. Our study suggests that dose of 517 mg per m2 of body surface area leads to amikacin levels most approaching target peak concentration. Dosing interval calculated as 228.7 × e-3.08× CKD-EPI creatinine clearance (mL s-1) + 15.84 most closely approximated optimal dosing intervals based on individual pharmacokinetics. The dosing nomogram based on CKD-EPI creatinine clearance was designed.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033698
- 003
- CZ-PrNML
- 005
- 20240522100317.0
- 007
- ta
- 008
- 181008s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/1120009X.2017.1376818 $2 doi
- 035 __
- $a (PubMed)28950787
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Šíma, Martin $u First Faculty of Medicine, Department of Pharmacology , Charles University and General University Hospital in Prague , Prague 2 , Czech Republic.
- 245 10
- $a Estimation of once-daily amikacin dose in critically ill adults / $c M. Šíma, J. Hartinger, T. Cikánková, O. Slanař,
- 520 9_
- $a This study aimed at investigating variables affecting amikacin pharmacokinetics in order to propose optimal initial dosing in critically ill adult patients treated with once-daily amikacin regimen. Amikacin pharmacokinetics was calculated based on plasma concentrations using one compartmental analysis. Relationships between pharmacokinetic parameters and demographic/clinical data were explored in linear regression models. Simulated dose and dosing intervals were derived from body size descriptors and estimated creatinine clearances for each patient. Amikacin volume of distribution best correlated with body surface area, while amikacin clearance was best predicted by CKD-EPI creatinine clearance. Our study suggests that dose of 517 mg per m2 of body surface area leads to amikacin levels most approaching target peak concentration. Dosing interval calculated as 228.7 × e-3.08× CKD-EPI creatinine clearance (mL s-1) + 15.84 most closely approximated optimal dosing intervals based on individual pharmacokinetics. The dosing nomogram based on CKD-EPI creatinine clearance was designed.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a amikacin $x aplikace a dávkování $x farmakokinetika $7 D000583
- 650 _2
- $a antibakteriální látky $x aplikace a dávkování $x farmakokinetika $7 D000900
- 650 12
- $a kritický stav $7 D016638
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a gramnegativní bakteriální infekce $x farmakoterapie $7 D016905
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Hartinger, Jan $u First Faculty of Medicine, Department of Pharmacology , Charles University and General University Hospital in Prague , Prague 2 , Czech Republic. $7 xx0224709
- 700 1_
- $a Cikánková, Tereza, $d 1986- $u First Faculty of Medicine, Department of Pharmacology , Charles University and General University Hospital in Prague , Prague 2 , Czech Republic. $7 xx0268197
- 700 1_
- $a Slanař, Ondřej $u First Faculty of Medicine, Department of Pharmacology , Charles University and General University Hospital in Prague , Prague 2 , Czech Republic.
- 773 0_
- $w MED00181505 $t Journal of chemotherapy $x 1973-9478 $g Roč. 30, č. 1 (2018), s. 37-43
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28950787 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20240522100313 $b ABA008
- 999 __
- $a ok $b bmc $g 1340256 $s 1030692
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 30 $c 1 $d 37-43 $e 20170927 $i 1973-9478 $m Journal of chemotherapy $n J Chemother $x MED00181505
- LZP __
- $a Pubmed-20181008
